Search
Curcumin
go.drugbank.com/drugs/DB11672ApprovedInvestigationalDue to these properties, curcumin has been investigated for the treatment and supportive care of clinical conditions including proteinuria, breast cancer, multiple myeloma, depression, and Non Small Cell … Despite proven efficacy against numerous experimental models, poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination have been shown to limit the therapeutic efficacy
Categories: Analgesics, Non-NarcoticPyrethrum extract
go.drugbank.com/drugs/DB11087ApprovedThe active compound is absorbed by the lice and destroys them by acting on their nervous systems but is thought to exert minimal effect on humans. … Pyrethrum-containing mixtures are used as a common insecticide to control specific pest species. Pyrethrum extract is also used used to treat head, body, and pubic lice infections.
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigational[A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.
Vibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigational[L12801] Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. … [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801]
DL-dimyristoylphosphatidylcholine
go.drugbank.com/drugs/DB11283ApprovedIt is used in commercial drug preparations to solubilize drugs for injection [A32711]
Edaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigational[L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. … [L44007] The oral suspension formulation of edaravone was approved by the FDA in May 2022 and by Health Canada in November 2022.
Mifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalIts inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. … As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome.
Categories: EstranesAminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnIn the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis. … Clinicians need to be aware of the characteristic teratologic effects of aminopterin and methotrexate.
Synonyms: N-(4-(((2,4-diamino-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acidLebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379] … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12
Retifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigationalBy blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. … [L45608,L45618] On March 2023, the FDA granted accelerated approval to retifanlimab for a different indication, the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).